The Stethoscope Just Got a Brain

A 200 year old tool can now flag heart failure, AFib, and valve disease in 15 seconds. Here's how, and what it actually changes.

Welcome Back,

The stethoscope hasn't really changed since 1816. A doctor listens, relies on years of trained ears, and makes a judgment call in the room. That's still how most checkups work today.

Now a wave of AI powered stethoscopes, led by companies like Eko Health, are adding a layer underneath that judgment call. The devices record heart sounds and electrical signals, run them through models trained on hundreds of thousands of patient records, and hand the clinician a result in about 15 seconds, flagging heart failure risk, atrial fibrillation, or valve disease before symptoms ever show up.

Today we look at how the technology actually works, what the clinical data says so far, and why "silent" heart disease has been so hard to catch until now.

🩺 How It Actually Works

Eko's device, about the size of a playing card, does two things a traditional stethoscope can't. It captures an ECG reading of the heart's electrical activity, and it records the sound of blood moving through the heart with far more fidelity than the human ear can pick up.

That combined data gets run through machine learning models trained on more than 100,000 paired ECG and echocardiogram recordings, according to research published in The Lancet. One of those models, recently cleared by the FDA, screens specifically for low ejection fraction, a marker of how well the heart is pumping blood and a key early sign of heart failure.

In a multisite study of 3,456 patients, the tool achieved an AUROC of 0.835 for detecting reduced ejection fraction, correctly identifying roughly 75% of true cases while keeping the false-positive rate low. That's a meaningfully strong result for something that happens during a routine 15-second listen.

The device fits in one hand, but the model behind it was trained on data from tens of thousands of patients.

🔍 Three Conditions, One Common Thread

Researchers behind a related British Heart Foundation-backed study found that AI-enabled stethoscopes could help doctors identify three specific conditions early: heart failure, atrial fibrillation, and valve disease. All three share the same core problem, they tend to get diagnosed late, often only after a patient shows up in the emergency room.

Dr. Patrik Bächtiger, a clinical lecturer at Imperial College London, put the contrast bluntly, noting that a tool designed nearly 200 years ago hadn't meaningfully changed until now, and that a 15-second exam can now deliver a result on all three conditions at once.

Atrial fibrillation is a good example of why this matters. It frequently produces no symptoms at all, which means patients and even routine physicals can miss it entirely, right up until it causes a stroke.

📊 What the Data Actually Shows

A separate study published in the European Heart Journal - Digital Health followed 357 patients aged 50 and older, each screened with both a traditional stethoscope and an AI-enabled digital one. The AI tool more than doubled the identification of moderate to severe valvular heart disease compared to the standard exam alone.

Roughly half of the 6 million-plus Americans living with heart failure have the reduced ejection fraction type the FDA-cleared tool screens for, a group traditional methods like echocardiography often miss early simply because that equipment is expensive and not always available in a primary care office.

Researchers say the tool's biggest value may be in primary care offices that lack access to specialized cardiac imaging.

🌍 Not Just One Company

Eko isn't working alone in this space. In the UK, the TRICORDER trial is running a cluster-randomised study across up to 200 primary care practices in London and rural Wales, testing whether giving clinicians an AI stethoscope, with no restrictions on which patients they use it on, actually changes outcomes at scale.

In Japan, researchers at Acute Medical Innovation built a comparable device called the Super StethoScope, with a 2024 study in the Journal of Cardiology showing it could help detect valvular heart disease and related conditions too.

The convergence matters. Multiple independent teams, in different health systems, building toward the same conclusion, that acoustic and electrical heart data plus machine learning can catch things a trained ear alone increasingly can't.

⚖️ What Still Needs to Be Proven

None of this means the tool replaces a cardiologist. It flags risk, it doesn't make a diagnosis, and every positive result still routes to further testing like an echocardiogram before treatment decisions get made.

A March 2025 paper in the Netherlands Heart Journal on early users of Eko's CORE 500 device made a similar point, that trust has to be earned through transparent reporting, strong clinical trials, and independent testing, not just a good demo.

For older patients with several risk factors, a 15-second screen at a routine visit could mean catching disease years before symptoms appear.

🧠 AI Spotlight Analysis

The interesting thing about this story isn't the AI, it's the delivery mechanism. Plenty of AI diagnostic tools have struggled to get adopted because they require new equipment, new workflows, or new appointments. This one rides inside a tool doctors already pick up dozens of times a day.

Eko co-founder Jason Bellet framed the goal as closing a diagnostic gap, arguing that better detection at the physical exam stage means patients get referred to cardiology faster and reach treatment sooner.

Heart disease often develops silently, which is exactly why a tool that adds detection without adding friction is worth paying attention to. The technology isn't asking patients to change anything about how they get care, it's making the checkup they already have more useful.

🔗 Sources and Further Reading

Thanks for reading AI Spotlight.

Our mission is simple: deliver clear, trustworthy, and actionable AI insights that help professionals stay ahead without the hype.